Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

M Fassnacht, G Assie, E Baudin, G Eisenhofer, C de la Fouchardiere, H R Haak, R de Krijger, F Porpiglia, M Terzolo, A Berruti, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, M Fassnacht, G Assie, E Baudin, G Eisenhofer, C de la Fouchardiere, H R Haak, R de Krijger, F Porpiglia, M Terzolo, A Berruti, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

No abstract available

Keywords: Clinical Practice Guidelines; adrenal cancer; diagnosis; follow-up; treatment.

Conflict of interest statement

Disclosure MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA, CdlF, GE, FP and Rdk have declared no potential conflicts of interest.